Bloomberg: Drug Reps Trade Swipes Over Report on Medicare Rx Spending

“This report finally debunks the myth that drugmakers have somehow been compelled to raise prices because of the discounts and rebates health plans and PBMs demand to reduce overall costs,” Mark Merritt,